ReviewClinical Importance of OATP1B1 and OATP1B3 in DrugDrug Interactions
References (93)
- et al.
The superfamily of organic anion transporting polypeptides
Biochim. Biophys. Acta
(2003) - et al.
A novel human hepatic organic anion transporting polypeptide (OATP2)
Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J. Biol. Chem.
(1999) - et al.
The organic anion transporter (OATP) family
Drug Metab. Pharmacokinet.
(2004) - et al.
Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide
J. Biol. Chem.
(2000) - et al.
LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers
Gastroenterology
(2001) - et al.
Transporters as a determinant of drug clearance and tissue distribution
Eur. J. Pharm. Sci.
(2006) - et al.
Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs
Drug Metab. Pharmacokinet.
(2008) - et al.
Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions
Pharmacol. Ther.
(2006) Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors
Am. J. Cardiol.
(2004)- et al.
Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers
Clin. Ther.
(2003)
Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients
Am. J. Transplant.
(2001)
Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A
Kidney Int.
(2000)
Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver
Pharmacol. Rev.
(1998)
General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs
Clin. Pharmacokinet.
(2007)
General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information
Clin. Pharmacokinet.
(2008)
In vitro techniques to study drug-drug interactions of drug metabolism: Cytochrome P450
Transporter-based drug-drug interactions and their effect on distribution volumes
Role of P-glycoprotein in drug disposition
Ther. Drug Monit.
(2000)
Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data
Curr. Drug Metab.
(2003)
The ABC transporters MDR1 and MRP2: multiple functions in disposition of xenobiotics and drug resistance
Drug Metab. Rev.
(2004)
P-glycoprotein-based drug-drug interactions: preclinical methods and relevance to clinical observations
Arch. Pharm. Res.
(2004)
Herbal modulation of P-glycoprotein
Drug Metab. Rev.
(2004)
P-glycoprotein-related drug interactions: clinical importance and a consideration of disease states
Expert Opin. Drug Metab. Toxicol.
(2010)
Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties
Pflugers Arch.
(2004)
Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination
Expert Opin. Drug Metab. Toxicol.
(2005)
Membrane transporters and drug response
A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane
Am. J. Physiol. Gastrointest. Liver Physiol.
(2000)
Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner
Endocrinology
(2001)
Human liver-specific organic anion transporter-2 is a potent prognostic factor for human breast carcinoma
Cancer Sci.
(2007)
Oatp2 mediates bidirectional organic solute transport: a role for intracellular glutathione
Mol. Pharmacol.
(2000)
Human organic anion transporter 1B1 and 1B3 function as bidirectional carriers and do not mediate GSH-bile acid cotransport
Am. J. Physiol. Gastrointest. Liver Physiol.
(2007)
Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics
Pharm. Res.
(1996)
Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients
Clin. Pharmacol. Ther.
(1999)
In vitro and in vivo correlation of the inhibitory effect of cyclosporin A on the transporter-mediated hepatic uptake of cerivastatin in rats
Drug Metab. Dispos.
(2004)
Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions
Drugs
(1998)
Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions
Mol. Pharm.
(2009)
Membrane transporters in drug development
Nat. Rev. Drug Discov.
(2010)
Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs
Expert Opin. Drug Metab. Toxicol.
(2009)
The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy
Pharmacogenomics J.
(2010)
SLCO1B1 variants and statin-induced myopathy¯a genomewide study
N. Engl. J. Med.
(2008)
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
Pharmacogenet. Genomics
(2006)
Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1
Drug Metab. Dispos.
(2005)
HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms
Pharmacogenet. Genomics
(2010)
Gender is an important determinant of the disposition of the loop diuretic torasemide
J. Clin. Pharmacol.
(2010)
The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics
Clin. Pharmacol. Ther.
(2010)
Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1)
Br. J. Clin. Pharmacol.
(2005)
Cited by (90)
Epicatechin exerts dual action to shield sickling and hydroxyurea-induced myelosuppression: Implication in sickle cell anemia management
2022, Toxicology and Applied PharmacologyMolecular targets of statins and their potential side effects: Not all the glitter is gold
2022, European Journal of PharmacologyIn silico evaluation of pharmacokinetics and acute toxicity of withanolides in Ashawagandha
2022, Phytochemistry Letters
Copyright © 2011 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.